SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Fairmount Funds Management LLC

CIK 0001802528 · 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA, 19428 · 267-262-5300

Reported Value
$946M
Q4 2023
Positions
16
Filings on Record
26
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Fairmount Funds Management LLC reported $946M in U.S.-listed holdings across 16 positions for Q4 2023.

Its largest position, AXSM, represents 19.8% of the portfolio.

Compared with Q3 2023, the fund opened 0 new positions and exited 4.

Portfolio Metrics

Turnover
+14.4%
vs prior filed quarter
Top-10 Concentration
+89.3%
share of reported value
Largest Position
+19.8%
Axsome Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $165MQ4 ’19Q1 ’20: $165MQ2 ’20: $224MQ3 ’20: $236MQ4 ’20: $280MQ4 ’20Q1 ’21: $237MQ2 ’21: $243MQ3 ’21: $275MQ4 ’21: $303MQ4 ’21Q1 ’22: $423MQ2 ’22: $437MQ3 ’22: $569MQ4 ’22: $630MQ4 ’22Q1 ’23: $581MQ2 ’23: $709MQ3 ’23: $831MQ4 ’23: $946MQ4 ’23Q1 ’24: $917MQ2 ’24: $885MQ3 ’24: $1.2BQ4 ’24: $1.0BQ4 ’24Q1 ’25: $645MQ2 ’25: $772MQ3 ’25: $1.1BQ4 ’25: $1.3BQ4 ’25Q1 ’26: $1.4Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 79.9%Other: 15.6%ADR: 4.5%
  • Common Stock · 79.9% · $756M
  • Other · 15.6% · $148M
  • ADR · 4.5% · $43M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SLNOEURSOLENO THERAPEUTICS INCSOLD OUT−1.14M0−$34M$0
IMVTIMMUNOVANT INCSOLD OUT−750.0K0−$29M$0
TRVITREVI THERAPEUTICS INCSOLD OUT−5.16M0−$11M$0
DBV TECHNOLOGIES SASOLD OUT−6.78M0−$9M$0
CATBUSDASTRIA THERAPEUTICS INCADDED+1.65M3.55M+$13M$27M
MERUS N VTRIMMED−1.16M717.3K−$25M$20M
ARGXARGENX SEADDED+29.2K112.9K+$2M$43M
NUVLNUVALENT INCTRIMMED−527.2K1.92M+$29M$142M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

16 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AXSMAXSOME THERAPEUTICS INChistory →COM19.85%$188M2.36M
2IMGNEURIMMUNOGEN INChistory →COM18.58%$176M5.93M
3NUVLNUVALENT INChistory →COM14.96%$142M1.92M
4APGEAPOGEE THERAPEUTICS INChistory →COM8.68%$82M2.94M
5RAYZEBIO INCCOM8.18%$77M1.25M
6KINIKSA PHARMACEUTICALS LTDCOM CL A5.34%$51M2.88M
7ARGXARGENX SEhistory →SPONSORED ADR4.54%$43M112.9K
8VRDNVIRIDIAN THERAPEUTICS INChistory →COM3.15%$30M1.37M
9ELVNENLIVEN THERAPEUTICS INChistory →COM3.12%$29M2.13M
10CATBUSDASTRIA THERAPEUTICS INChistory →COM2.88%$27M3.55M
11COGTCOGENT BIOSCIENCES INChistory →COM2.21%$21M3.56M
12DNTHDIANTHUS THERAPEUTICS INChistory →COM2.12%$20M1.93M
13MERUS N VCOM2.08%$20M717.3K
14TYRATYRA BIOSCIENCES INChistory →COM2.04%$19M1.39M
15430TERNS PHARMACEUTICALS INChistory →COM1.40%$13M2.04M
16SYRESPYRE THERAPEUTICS INCCOM NEW0.86%$8M378.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.4B12May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.3B13Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.1B17Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$772M17Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$645M15May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.0B17Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.2B15Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$885M13Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$917M15May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$946M16Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$831M20Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$709M17Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$581M16May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$630M16Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$569M27Nov 9, 202213F-HRchanges · EDGAR ↗
Q2 2022$437M27Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$423M22May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$303M20Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$275M20Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$243M19Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$237M21May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$280M18Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$236M17Nov 12, 202013F-HRchanges · EDGAR ↗
Q2 2020$224M14Aug 4, 202013F-HRchanges · EDGAR ↗
Q1 2020$165M14May 8, 202013F-HRchanges · EDGAR ↗
Q4 2019$165M15Feb 12, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.